看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
+ ~ ]$ B( @. t$ s6 _% ^/ u; e2 e% I6 }! O1 q7 T3 b* e
1 M, D# M* O/ _5 T! t8 J! E- ?
Currently available feasibility data for possible combination strategies. , x2 Y1 Q2 c0 \7 R% d
————————————————————————————————
% T* K( C- ]4 [, ?- {Combination Feasibility according to preliminary data
0 h# P6 s m% y, ^; ~3 O. i——————————————————————————————————
" @5 D9 @$ t& I5 d& t$ h- @Bevacizumab + sorafenib Yes, reduced dose 2 N+ P5 ^) k2 o" N. K
Bevacizumab + sunitinib† No 2 t5 y) C" j# p0 h
Bevacizumab + temsirolimus Yes 1 w: |. B6 u9 X( I2 r; Q
Bevacizumab + everolimus Yes - q. m% ~6 i' L( z% s
Sorafenib + sunitinib ?
( B( k u: J4 F# O" `) `Sorafenib + temsirolimus Yes, reduced dose " o7 ^8 b3 i- j
Sorafenib + everolimus Yes, reduced dose ! Q- x, q1 P) D& i
Sunitinib + temsirolimus† No 0 J- D9 U4 O2 A+ W. b! l3 O. c8 s
Sunitinib + everolimus ? ( v( ]1 \# B. b4 U# z k1 I$ T( S
Temsirolimus + everolimus ?
2 j8 s$ d1 J! m, U1 W/ S+ O————————————————————* R! o- g+ I8 C" k& N$ v3 }
†Led to US FDA warning.
, A* t( K: g4 h. q" _* X: [) J?: As yet unattempted combination.
& C1 E4 s1 l- c |